Orgenesis Inc., the mother company of Masthercell,
announced that its common stock has been approved for listing on the NASDAQ Capital Market. For more information please read March 12th NASDAQ Global Wire publication.
Bone Therapeutics raises €19.45M of commitments in convertible bond placement
This placing will support Bone Therapeutics in the development of its unique pipeline of cell therapy products. Congratulations ! For more information, please read March 7th 2018 publication in L'Echo.